Castle Biosciences (CSTL) Non-Current Assets (2018 - 2026)
Castle Biosciences' Non-Current Assets history spans 8 years, with the latest figure at $217.5 million for Q4 2025.
- On a quarterly basis, Non-Current Assets rose 27.11% to $217.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $771.1 million, a 15.0% increase, with the full-year FY2025 number at $217.5 million, up 27.11% from a year prior.
- Non-Current Assets hit $217.5 million in Q4 2025 for Castle Biosciences, up from $205.2 million in the prior quarter.
- Over the last five years, Non-Current Assets for CSTL hit a ceiling of $217.5 million in Q4 2025 and a floor of $10.7 million in Q1 2021.
- Historically, Non-Current Assets has averaged $142.5 million across 5 years, with a median of $156.4 million in 2023.
- Biggest five-year swings in Non-Current Assets: skyrocketed 1018.03% in 2021 and later dropped 6.39% in 2025.
- Tracing CSTL's Non-Current Assets over 5 years: stood at $108.8 million in 2021, then skyrocketed by 42.46% to $155.0 million in 2022, then grew by 1.72% to $157.7 million in 2023, then increased by 8.48% to $171.1 million in 2024, then increased by 27.11% to $217.5 million in 2025.
- Business Quant data shows Non-Current Assets for CSTL at $217.5 million in Q4 2025, $205.2 million in Q3 2025, and $196.1 million in Q2 2025.